GlassScriptPhysician profile
John F Villa
NPI 1457328205
$1,125.70
in general payments reported to CMS, 2019-2025
11 companies · $101 in 2025
The $101 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.24 · 2020: $45.09 · 2021: $184 · 2022: $157 · 2023: $290 · 2024: $333 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $463.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $305.90 | 2022-2025 | Dupixent |
| Impulse Dynamics (USA) INC. | $178.29 | 2024 | Optimizer |
| Lilly USA, LLC | $32.44 | 2024-2025 | Zepbound |
| Novo Nordisk INC | $32.37 | 2021-2025 | Wegovy |
| Alkermes, INC. | $26.49 | 2023 | Vivitrol |
| Glaxosmithkline, LLC. | $20.48 | 2022 | |
| Alfasigma USA, INC. | $18.22 | 2022 | |
| Seqirus USA INC | $17.82 | 2021 | |
| Abbvie INC. | $16.29 | 2023 | Vraylar |
| Adlon Therapeutics L.P. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.